| |
original article |
Journal |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Sep―16 |
Acute inflammatory demyelinating pseudotumor after COVID-19 |
T. I. Yakushina, D. M. Yakushin, I. O. Shtang |
| 2 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Sep―16 |
Current ethical issues of clinical trials of drugs for the pathogenetic therapy of multiple sclerosis in the context of the COVID-19 pandemic |
E. V. Ivashkova, A. M. Petrov, M. V. Votintseva, I. D. Stolyarov |
| 3 |
[GO] |
Modern Rheumatology Journal |
2021―Aug―16 |
Septal panniculitis as manifestation of COVID-19: own data |
O. N. Egorova, R. G. Goloeva, D. I. Abdulganieva |
| 4 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Jun―24 |
COVID-19 and epilepsy: Russian and international experience |
G. V. Odintsova |
| 5 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Jun―24 |
Management tactics in patients with chronic cerebral ischemia during COVID-19 pandemic |
A. A. Kulesh |
| 6 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
Actovegin use in patients with cognitive impairment after coronavirus infection (COVID-19) |
V. A. Kutashov |
| 7 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
COVID-19 vaccination guidelines for patients with multiple sclerosis |
N. V. Khachanova, N. A. Totolyan, Ya. V. Vlasov, S. A. Sivertseva, M. V. Davydovskaya, E. P. Evdoshenko, et al. (+4) A. P. Prodeus, M. N. Zakharova, N. N. Spirin, A. N. Boyko |
| 8 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
Cognitive impairment in COVID-19: associations, pathogenesis and treatment questions |
V. A. Golovacheva, G. R. Tabeeva, I. V. Kuznetsov |
| 9 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
Anxiety and depression in COVID-19: treatment options |
V. E. Medvedev |
| 10 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
Central pontine myelinolysis in the presence of SARS-CoV-2 infection (clinical observations) |
O. N. Voskresenskaya, A. A. Kovalenko, E. B. Nadbitova, V. V. Grinyuk, A. V. Klimanov, Yu. M. Shor |
| 11 |
[GO] |
Modern Rheumatology Journal |
2021―Apr―24 |
The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 |
E. S. Aronova, B. S. Belov |
| 12 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Feb―18 |
The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’ |
V. V. Kovalchuk |
| 13 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Feb―18 |
Anxiety: phenomenology, epidemiology, and risk factors during the novel coronavirus SARS-CoV-2 (COVID-19) pandemic |
A. G. Merkin, S. S. Akinfieva, A. V. Martyushev-Poklad, O. P. Beloskurskaya, E. N. Dinov, S. L. Ostrovsky, et al. (+5) A. N. Komarov, O. Yu. Zakharova, V. A. Kazhin, I. A. Nikiforov, M. Glover |
| 14 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Feb―18 |
Depression during the COVID-19 pandemic (analysis of clinical cases) |
I. Yu. Dorozhenok |
| 15 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Feb―18 |
Cognitive impairment in COVID-19 survivors |
T. M. Ostroumova, P. A. Chernousov, I. V. Kuznetsov |
| 16 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2020―Dec―13 |
COVID-19 and mental health: challenges and first conclusions |
V. E. Medvedev, O. A. Dogotar |
| 17 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2020―Dec―13 |
Somatization disorders of affective and neurotic registers during the COVID-19 pandemic (analysis of clinical cases) |
I. Yu. Dorozhenok |
| 18 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2020―Aug―05 |
Nervous system damage in COVID-19 with an emphasis on the management of patients with multiple sclerosis |
A. N. Boyko, S. A. Sivertseva, N. N. Spirin |
| 19 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2020―Jun―26 |
The first experience with Angiovit in the combination treatment of acute COVID-19 infection |
A. N. Boyko, N. A. Shamalov, O. V. Boyko, E. E. Arinina, O. V. Lyang, E. A. Dubchenko, et al. (+2) A. V. Ivanov, A. A. Kubatiev |
| 20 |
[GO] |
Rheumatology Science and Practice |
2020―Jun―24 |
DO NSAIDS CAUSE SPECIFIC COMPLICATIONS IN COVID-19 CORONAVIRUS INFECTION? |
A. E. Karateev, E. L. Nasonov, A. M. Lila |
| 21 |
[GO] |
Rheumatology Science and Practice |
2020―Jun―24 |
IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6 |
E. L. Nasonov |
| 22 |
[GO] |
Modern Rheumatology Journal |
2020―May―31 |
COVID-19: the new challenge for rheumatologists |
B. S. Belov, A. E. Karateev |
| 23 |
[GO] |
Rheumatology Science and Practice |
2020―Apr―27 |
CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS |
E. L. Nasonov |
